NCT07128251View on ClinicalTrials.gov

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

January 30, 2028

Study Completion Date

December 30, 2029

Conditions
Hepatocellular Carcinoma (HCC)ImmunotherapyPD-1CTLA-4TACE
Interventions
PROCEDURE

TACE treatment

TACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted.

DRUG

Iparomlimab and Tuvonralimab Injection (QL1706)

Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.

DRUG

Bevacizumab

Bevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.

All Listed Sponsors
collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Henan Provincial People's Hospital

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Shaanxi Provincial Cancer Hospital

OTHER

collaborator

Xi'an International Medical Center Hospital

OTHER

collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

lead

Anhui Provincial Hospital

OTHER_GOV